Every 8-K that Definitive Healthcare Corp. (DH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DH filings page.
Definitive Healthcare Corp. (DH) reports that the holders under its existing Tax Receivable Agreement (TRA) have agreed among themselves to an irrevocable waiver of any right to receive an Early Termination Payment in connection with a Qualifying Change of Control, defined as a Change of Control whose definitive merger agreement is executed on or before December 31, 2026.
For any such Qualifying Change of Control that is consummated, the TRA will terminate in accordance with its terms, and the TRA parties will take actions reasonably necessary to effect that termination. All other rights under the TRA, including rights to tax benefit payments for taxable years ending prior to, with, or including the consummation of a Qualifying Change of Control, remain unchanged. Definitive Healthcare is not a party to this waiver; it is being described for informational purposes under Regulation FD.
Definitive Healthcare Corp. (DH) disclosed that a Special Committee of its board has received a non-binding indication of interest from Advent International, on behalf of certain managed funds, to take the company private. Advent proposes to acquire all outstanding shares of Class A common stock and Definitive OpCo Units that are not already owned by Advent or founder and Executive Chairman Jason Krantz for an all-cash price of $1.02 per share of Class A common stock and an equivalent amount per Definitive OpCo Unit.
The Special Committee, composed entirely of disinterested and independent directors, will review the proposal with independent legal and financial advisors and evaluate potential alternatives. No decisions have been made, no stockholder action is required at this time, and there is no assurance that any transaction or other strategic outcome will be approved or completed.
Definitive Healthcare Corp. (DH) announced that its Board appointed Clay Ritchey as Chief Executive Officer and director, effective September 8, 2026, under an employment agreement dated August 28, 2026. Ritchey brings more than 25 years of leadership experience at healthcare-focused technology and data companies, including Verato and Evariant.
Under his agreement, Ritchey will receive a $500,000 annual base salary, a target annual bonus equal to 87.5% of base salary, and eligibility for annual equity awards with an initial target of at least $2,000,000. He will also receive a one-time New Hire Equity Incentive valued at $4,000,000, split between time-based and performance-based restricted stock units.
The company disclosed severance protections for certain terminations, including salary continuation, bonus payments, and equity vesting benefits, with enhanced terms if a qualifying termination occurs in connection with a Change in Control. Definitive Healthcare also reported that prior CEO Kevin Coop stepped down as CEO and director effective August 31, 2026, and that his departure was not due to any disagreement regarding company operations, policies, or practices.
Definitive Healthcare Corp. reported second quarter 2026 revenue of $55.2 million, down from $60.8 million in Q2 2025. GAAP net loss narrowed to $7.5 million (14% of revenue) from $9.3 million (15% of revenue), while adjusted net income declined to $7.5 million from $9.7 million.
Adjusted EBITDA was $14.6 million, a 26% margin compared with $18.7 million and a 31% margin a year earlier. Cash flow from operations was strong at $11.5 million, and unlevered free cash flow was $11.6 million. Cash and cash equivalents rose to $170.9 million at June 30, 2026, with a term loan balance of about $160.6 million.
For Q3 2026, the company guides revenue to $54.0–$55.0 million and adjusted EBITDA of $13.5–$14.5 million (25–27% margin. For full year 2026, it expects revenue of $220.0–$222.0 million, adjusted EBITDA of $57.0–$59.0 million, and adjusted net income of $27.0–$29.0 million. Management highlighted improving net dollar retention, win-back momentum, and the launch of Turbo, an AI-powered healthcare intelligence platform.
Definitive Healthcare Corp. has been notified by Nasdaq that its common stock no longer meets the $1.00 per share minimum bid price required for continued listing on the Nasdaq Global Select Market. The deficiency is based on 30 consecutive business days from May 6, 2026 to June 17, 2026.
The company has 180 calendar days, until December 15, 2026, to regain compliance. Nasdaq will deem the company compliant if the closing bid price is at least $1.00 per share for a minimum of ten consecutive business days, or longer if Nasdaq requires.
If the company does not regain compliance in this initial period, it may qualify for an additional 180-day period by meeting other Nasdaq Capital Market initial listing standards and potentially using actions such as a reverse stock split. The notice does not immediately affect trading, and the stock will continue to trade under the symbol DH while the company evaluates its options.
Definitive Healthcare Corp. reported the results of its 2026 annual meeting of stockholders. Shareholders elected three Class II directors to terms running until the 2029 annual meeting, with each nominee receiving over 114 million votes in favor and sizable broker non-votes.
Stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 130,745,809 votes for and limited opposition. They also approved increasing the shares authorized under the 2021 Equity Incentive Plan by 15,000,000, taking the plan reserve from 30,972,789 to 45,972,789, and supported, on a non-binding advisory basis, the compensation of named executive officers.
Definitive Healthcare Corp. reported Q1 2026 results with revenue of $55.9 million, down 6% from $59.2 million in Q1 2025. The company recorded a large GAAP net loss of $192.4 million, driven by $197.2 million of goodwill impairment, but generated positive non-GAAP profitability and cash flow.
Adjusted Net Income rose to $8.5 million and Adjusted EBITDA increased to $15.3 million, or 27% of revenue. Operating cash flow was $11.6 million and Unlevered Free Cash Flow was $18.0 million. Management highlighted performance at or above the high end of guidance and noted improving retention.
For full year 2026, the company expects revenue of $220.0–$226.0 million, Adjusted EBITDA of $55.0–$59.0 million (25%–26% margin), and Adjusted Net Income of $23.0–$27.0 million.
Definitive Healthcare Corp. reported that it has ended a prior governance arrangement with an affiliate of Spectrum. The company and SE VII DHC AIV, L.P. entered into a termination agreement on April 3, 2026 that permanently and irrevocably ended their 2021 Nominating Agreement.
That Nominating Agreement had allowed Spectrum, while it beneficially owned at least 5% of the company’s outstanding common stock, to designate one person for inclusion in the board slate (the “Spectrum Designee”). Jeff Haywood, the Spectrum Designee, resigned from the board on March 30, 2026, and the nominating rights have now been fully terminated.
Definitive Healthcare Corp. reported that on March 30, 2026, director Jeff Haywood resigned from its Board of Directors and from the Board’s Human Capital Management and Compensation Committee, effective immediately. The company stated that his resignation was not due to any disagreement regarding its operations, policies, or practices.
Following his departure, the Board size was reduced from nine members to eight members, and the Compensation Committee was reduced from three members to two members, reflecting his departure rather than adding a replacement director at this time.
Definitive Healthcare reported mixed 2025 results with improving profitability metrics but lower revenue. Q4 2025 revenue was $61.5 million, down 1% from $62.3 million in Q4 2024, while Adjusted EBITDA rose slightly to $18.0 million, or 29% of revenue, from $17.5 million and 28% a year earlier. Q4 net loss narrowed sharply to $17.1 million, including $19.5 million of goodwill impairment, compared with an $84.7 million loss including $97.1 million of impairment in Q4 2024.
For full year 2025, revenue was $241.5 million versus $252.2 million in 2024. Net loss was $199.3 million, including $196.1 million in goodwill impairment, improving from a $591.4 million loss with $688.9 million of impairment in 2024. Adjusted EBITDA was $70.4 million, or 29% of revenue, down from $79.1 million and a 31% margin. Operating cash flow reached $53.8 million and Unlevered Free Cash Flow was $54.9 million.
For 2026, the company guides revenue to $220.0–$226.0 million, Adjusted EBITDA to $53.0–$58.0 million with a 24–26% margin, and Adjusted Net Income to $21.0–$26.0 million, or $0.14–$0.17 per diluted share.
Definitive Healthcare Corp. (DH) reported a filing action. The company furnished an Item 2.02 Form 8‑K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The company states the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and is not subject to Section 18 liabilities nor incorporated by reference into other filings.